Can we rationally design promiscuous drugs?

[1]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[2]  Ronald W. Davis,et al.  Role of duplicate genes in genetic robustness against null mutations , 2003, Nature.

[3]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[4]  J. Halpert,et al.  Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.

[5]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[6]  Charles Kung,et al.  Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jan Balzarini,et al.  Phenylethylthiazolylthiourea (PETT) Non-nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases , 2000, The Journal of Biological Chemistry.

[8]  Dan S. Tawfik,et al.  The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.

[9]  A. Brown.  HERG block, QT liability and sudden cardiac death. , 2005, Novartis Foundation symposium.

[10]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[11]  Andrew Howard,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .

[12]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[13]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Gary D Bader,et al.  Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.

[15]  T. Hampton,et al.  "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. , 2004, JAMA.

[16]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[17]  B. Berkhout.  HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness , 1999, Journal of Biomedical Science.

[18]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[19]  Joel L. Sussman,et al.  Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica , 1998, Journal of Physiology-Paris.

[20]  Simon K. Mencher,et al.  Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.

[21]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[22]  J. Casida,et al.  Detoxification of α- and β-Thujones (the Active Ingredients of Absinthe): Site Specificity and Species Differences in Cytochrome P450 Oxidation in Vitro and in Vivo , 2001 .

[23]  S. Lindquist,et al.  Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.

[24]  D. Stuart,et al.  Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[26]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[27]  M. Newman.  Properties of highly clustered networks. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[28]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[29]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[30]  D I Stuart,et al.  Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.

[31]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[32]  L. Moore,et al.  The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity , 2001, Science.

[33]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[34]  A. Fliri,et al.  Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.

[35]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[36]  Alex M Aronov,et al.  Toward a pharmacophore for kinase frequent hitters. , 2004, Journal of medicinal chemistry.

[37]  B. Garvik,et al.  Principles for the buffering of genetic variation. , 2001 .

[38]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[39]  Erik De Clercq,et al.  The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .

[40]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[41]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[42]  Gennady M Verkhivker,et al.  Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. , 1996, Proteins.

[43]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[44]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[45]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[46]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[47]  Gabriele Cruciani,et al.  Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.

[48]  L. Moore,et al.  Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. , 2005, Molecular endocrinology.

[49]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[50]  Beyond CAR and PXR. , 2005, Current drug metabolism.

[51]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[52]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[53]  M. Redinbo.  Promiscuity: what protects us, perplexes us. , 2004, Drug discovery today.

[54]  D. Stammers,et al.  The Phenylmethylthiazolylthiourea Nonnucleoside Reverse Transcriptase (RT) Inhibitor MSK-076 Selects for a Resistance Mutation in the Active Site of Human Immunodeficiency Virus Type 2 RT , 2004, Journal of Virology.

[55]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[56]  Andrzej Kloczkowski,et al.  Protein Promiscuity: Drug Resistance and Native Functions—HIV-1 Case , 2005, Journal of biomolecular structure & dynamics.

[57]  David I Stuart,et al.  Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. , 2004, Journal of medicinal chemistry.

[58]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[60]  L. Moore,et al.  The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution , 2000 .

[61]  F. Gonzalez.  Cytochrome P450 humanised mice , 2004, Human Genomics.

[62]  Albert,et al.  Emergence of scaling in random networks , 1999, Science.

[63]  Celia A Schiffer,et al.  Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.

[64]  Jean-Pierre Marquette,et al.  SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.

[65]  Gennady M Verkhivker,et al.  Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Kazuo Koyama,et al.  A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. , 2003, Bioorganic & medicinal chemistry.

[67]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[68]  A. Wagner.  Robustness against mutations in genetic networks of yeast , 2000, Nature Genetics.

[69]  Celia A Schiffer,et al.  Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.

[70]  W. Sneader.  Drug prototypes and their exploitation , 1996 .

[71]  Turning from monogamy to strategic promiscuity. , 2004, Drug discovery today.